Kageyama Y, Takahashi M, Ichikawa T, Torikai E, Nagano A
Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Clin Exp Rheumatol. 2008 Jan-Feb;26(1):73-80.
The aim of this study was to evaluate the effects of anti-TNF-alpha antibody, infliximab, on oxidative stress markers representing DNA damage, lipid peroxidation, and glycoxidation.
Twenty-three RA patients underwent infliximab treatment and were analyzed for 30 weeks. Six patients who experienced side effects and one patient who had a reduced efficacy of infliximab were discontinued the infliximab treatment at 30-54 weeks. Sixteen patients were analyzed for 54 weeks. The levels of serum total, urinary total, and free pentosidine, which is an advanced glycation end-product (AGE), and of urinary 15-Isoprostane F2t and 8-hydroxy-deoxy guanosine (8-OHdG) were determined at baseline and at 14, 30, and 54 weeks after initial treatment with infliximab.
Serum total, urinary total, and free pentosidine levels were reduced at 54 weeks after initial infliximab treatment. Urinary 15-Isoprostane F2t and 8-OHdG levels were also reduced at 14, 30, and 54 weeks. Urinary 8-OHdG levels in RA patients correlated with CRP and the Disease Activity Score of 28 joints.
In RA patients, infliximab plays an essential role as an anti-oxidative agent against AGE formation, oxidative DNA damage and lipid peroxydation.
本研究旨在评估抗TNF-α抗体英夫利昔单抗对代表DNA损伤、脂质过氧化和糖氧化的氧化应激标志物的影响。
23例类风湿关节炎（RA）患者接受英夫利昔单抗治疗，并进行30周的分析。6例出现副作用的患者和1例英夫利昔单抗疗效降低的患者在30 - 54周时停止英夫利昔单抗治疗。16例患者进行54周的分析。在基线以及英夫利昔单抗初始治疗后的第14、30和54周，测定血清总戊糖苷、尿总戊糖苷和游离戊糖苷（一种晚期糖基化终产物（AGE））的水平，以及尿15-异前列腺素F2t和8-羟基脱氧鸟苷（8-OHdG）的水平。
初始英夫利昔单抗治疗后54周，血清总戊糖苷、尿总戊糖苷和游离戊糖苷水平降低。尿15-异前列腺素F2t和8-OHdG水平在第14、30和54周时也降低。RA患者的尿8-OHdG水平与CRP及28个关节疾病活动评分相关。
在RA患者中，英夫利昔单抗作为一种抗氧化剂，在对抗AGE形成、氧化性DNA损伤和脂质过氧化方面发挥着重要作用。
